Entries of Adekola, Kehinde on the publication server
 | Up a level |
Number of items: 1.
Al Malki, Monzr M., London, Kaitlyn, Baez, Janna, Akahoshi, Yu 
, Hogan, William J. , Etra, Aaron, Choe, Hannah, Hexner, Elizabeth , Langston, Amelia , Abhyankar, Sunil, Ponce, Doris M., DeFilipp, Zachariah, Kitko, Carrie L., Adekola, Kehinde, Reshef, Ran, Ayuk, Francis, Capellini, Alexandra, Chanswangphuwana, Chantiya, Eder, Matthias, Eng, Gilbert, Gandhi, Isha, Grupp, Stephan, Gleich, Sigrun, Holler, Ernst, Javorniczky, Nora Rebeka, Kasikis, Stelios, Kowalyk, Steven, Morales, George, Özbek, Umut, Rösler, Wolf, Spyrou, Nikolaos, Yanik, Gregory, Young, Rachel, Chen, Yi-Bin, Nakamura, Ryotaro, Ferrara, James L. M. and Levine, John E.
(2023)
Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease.
Blood Advances 7 (17), pp. 5189-5198.
Fulltext not available.
, Hogan, William J. , Etra, Aaron, Choe, Hannah, Hexner, Elizabeth , Langston, Amelia , Abhyankar, Sunil, Ponce, Doris M., DeFilipp, Zachariah, Kitko, Carrie L., Adekola, Kehinde, Reshef, Ran, Ayuk, Francis, Capellini, Alexandra, Chanswangphuwana, Chantiya, Eder, Matthias, Eng, Gilbert, Gandhi, Isha, Grupp, Stephan, Gleich, Sigrun, Holler, Ernst, Javorniczky, Nora Rebeka, Kasikis, Stelios, Kowalyk, Steven, Morales, George, Özbek, Umut, Rösler, Wolf, Spyrou, Nikolaos, Yanik, Gregory, Young, Rachel, Chen, Yi-Bin, Nakamura, Ryotaro, Ferrara, James L. M. and Levine, John E.
(2023)
Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease.
Blood Advances 7 (17), pp. 5189-5198.
Fulltext not available.